• Disease response after course 2 and then every 3 months [ Designated as safety issue: No ]
  
• Survival every 3 months [ Designated as safety issue: No ]
  
• Toxicity as assessed by physical exam and laboratory tests on days 1 and 22 of courses 1 and 2 and on day 84 [ Designated as safety issue: Yes ]
  

• Quality of life as assessed by the Functional Living Index-Cancer and the Brief Symptom Inventory on days 1 and 2 of courses 1 and 2 and on day 84 [ Designated as safety issue: No ]
  

OBJECTIVES:

• Determine the objective response rate, response duration, and survival of patients with AIDS-related non-Hodgkin's lymphoma treated with lomustine, etoposide, cyclophosphamide, and procarbazine.
• Determine the feasibility of this regimen in these patients.
• Determine the clinical toxicity of this regimen in these patients.
• Assess the quality of life of patients treated with this regimen.
• Determine the impact of this regimen on the underlying HIV infection in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral lomustine on day 1 (course 1 only), oral etoposide on days 1-3, and oral cyclophosphamide and oral procarbazine on days 22-26. Patients may also receive filgrastim (G-CSF) subcutaneously on days 5-21 and 28-42. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, on days 1 and 22 of each course, at day 84, and then every 3 months for 1 year.

Patients are followed at day 84 and then every 3 months.

PROJECTED ACCRUAL: A total of 66 patients (22 in the United States and 44 in Africa) will be accrued for this study within 3-4 years.